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Abstract Montelukast, a specific cysteinyl leukotriene receptor antagonist, has been shown to improve pulmonary
functionwithin1hof ingestion.This studywasundertakento comparethe effects onpeakexpiratory flowrate (PEFR) of
oralmontelukast added to intravenous steroid, intravenous steroid alone and placebo during the 24 h period following
administration.Seventyasthmaticpatients (FEV140^80%predictedand15% improvementafterinhaled bagonist)were
enrolled in a single blind study to receive oralmontelukast (10mg) plus intravenous prednisolone (1mg/kg), intravenous
prednisolone (1mg/kg) orplacebo in a randomised fashion.The patients received one ofthe above three groups ofmed-
ication before anyother treatments.Thiswas immediately followed by the aerosol treatments of100mcg of terbutaline
sulphate divided intothree doses during1h as described inthe consensus statement.Thereafter, patientswere observed
for 24 h to documentthe effects on PEFR,Borg dyspnoea score and need for rescuemedication.The primary end point
waspercentage change atdifferenttimepoints.Secondaryendpointswere Borgdyspnoea score anduse ofrescuemed-
ication.Compared with placebo, montelukast added to the prednisolone group and the prednisolone alone group had
significant percentage change frombaseline in PEFR in the entire 24 h period (Po0.05).The difference in PEFR between
montelukastplusprednisolonegroup andprednisolonegroup favouredthemontelukastplusprednisolonegroupbutdid
notreach statistical significance.Furthermore, montelukastplusprednisolonegrouprequiredlessinhaled short-acting b
agonistthan other two groups.The results of this study indicate that addingmontelukastto steroid in acute asthmamay
have some additive improvement in lung functions. r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2003.1479, available online athttp://www.sciencedirect.com
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Asthma is de¢ned as a chronic in£ammatory disease of
the airways. It a¡ects approximately10% of children and
5% of adults worldwide.The incidence of asthma has in-
creased substantially. In addition, the number of patients
presenting to emergency room departments with acute
asthma exacerbations has also increased.Despite better
understanding of its pathogenesis, drug treatment for
acute asthma has changed little over the last two dec-
ades (1).
Corticosteroids have become the standard of care in
the emergency department management of acute asth-
ma. Although corticosteroids are believed to be the
most potent anti-in£ammatory agents available, they do
not suppress all in£ammatory mediators such as leuko-
trienes synthesis or release (2). Leukotrienes are potent
in£ammatory mediators that play an important role inReceived 28 May 2002, accepted in revised form17 December 2002
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242 2274490; E-mail: acilli@med.akdeniz.edu.trasthma pathogenesis. In chronic asthma, antileukotriene
drugs have been shown to have additive bene¢ts with b
agonists, corticosteroids and theophylline (3). Recently,
it has been shown that single oral doses of montelukast,
a potent, speci¢c, orally active cysteinyl receptor an-
tagonist has a capability of producing signi¢cant increase
in FEV1 (4). This suggested to us that antileukotrienes
may have a complementary e¡ect in acute asthma man-
agement.
This study was undertaken to show whether adding
an oral leukotriene receptor antagonist, montelukast
will produce further improvements in patients with
acute asthma who have already received ¢rst line treat-
ment including inhaled terbutaline and corticosteroids.
PATIENTSANDMETHODS
Seventy patients with at least a 1y history of chronic
asthma, an FEV1of 40^80% predicted, and with aZ15%
improvement in FEV1 after inhaled b agonist were en-
rolled.Thebaseline characteristicswere comparable be-
tween the treatment groups (Table 1). The current
TABLE 1. Baseline characteristics of patientsa
Characteristics Steroid
(n=22)
Steroid+montelukast
(n=23)
Placebo
(n=25)
Age (year) 64.677.6 64.077.7 64.278.2
Sex (M/F) 7/15 7/16 8/17
BMI (kg/m2) 26.578.3 25.477.8 26.778.6
Duration of asthma (years) 8.276.5 8.577.0 8.977.1
FEV1 (% of predicted)b 58.7716.0 54.6714.4 56.8714.9
FVC (% of predicted)b 58.7716.0 55.4713.9 59.6710.6
PEFR (l/min)b 217.2766.6 194.7740.5 220.8771.2
aValuesgiven asmean7SD.
bMeasurements taken just before drugadministration.
534 RESPIRATORYMEDICINEasthma treatments of the patients were similar in all
groups. Eleven of the 70 patients were not receiving any
regular asthma medication. Nine patients were using
only short acting inhaled b-agonist as needed, and 50 pa-
tientswere using both inhaled corticosteroids on a regu-
lar basis and short-acting inhaled b-agonist as needed.
Patients were eligible to participate if they were cur-
rently non-smokers and had not taken oral, intravenous,
or intramuscular corticosteroids during themonth prior
to the startof the study.Those taking long acting antihis-
tamines within 2 weeks, or theophylline, oral or long-
acting inhaled b agonists, cromolyn sodium or nedocro-
mil, or inhaled anticholinergics within 1week, or short-
acting antihistamines during the 48h before the visit
were excluded. The study was approved by local ethics
committees and the patients gavewritten informed con-
sent. Acute exacerbation is de¢ned as episodes of pro-
gressively worsening shortness of breath within 24h,
cough, wheezing, or chest tightness, the episode is char-
acterised by decrease in expiratory £ow (FEV1 or PE-
FRo20% baseline).
Seventeen patients were seen in the outpatient clinic
and 53 patients were seen in the emergency room. After
that, all thepatientswerehospitalisedregardless of their
asthma severity for at least 24h follow-up.
This was a single blind (patient), randomised, placebo-
controlled study. After verifying entry criteria, baseline
measurements of peak expiratory £ow rates and FEV1
were obtained. Immediately thereafter, patientswere al-
located randomly to receive oral montelukast (Singulair
10mg tablet,Merck SharpDohme) plus intravenous ster-
oid (Prednisolone 1mg/kg), intravenous steroid alone
(prednisolone 1mg/kg) and placebo during a 24h treat-
ment period.
Patients received one of the above three medications
before any other emergency department treatments.
This was immediately followed by three aerosol treat-
ments of 0.5mg of terbutaline sulphate as dry powder
inhaler (Bricanyl turbuhaler 0.5mg, AstraZeneca, S˛-
dertMlje, Sweden) separated by 20-min intervals; there-after, patients were observed for 24h to document the
e¡ects on PEFR, Borg dyspnoea score and need for res-
cuemedication.Physical examinations, vital signs, side ef-
fects evaluation were performed. PEFR measurements
were done with peak £ow meter (Astech, Center La-
boratories, Port Washington, NY) and conducted 5min
before administration of the studydrug and 0.25, 0.5,1, 2,
4, 8,16, and 24h afterwards in the study protocol.
The primary end point was percentage change from
baseline in PEFR at each measured time point following
treatment. Secondary end points were Borg dyspnoea
score and proportion of patients requiring rescue medi-
cation.The percentage change from baseline in PEFR at
di¡erent time points following treatmentwas calculated
at each post-randomised time point after drug adminis-
tration (0.25, 0.5,1, 2, 4, 8,16, and 24h).
Repeated measure of ANOVAwas used for analysing
the di¡erencebetween subsequent PEFRmeasurements.
For the analysis of di¡erence in Borg dyspnoea score
within groups, Friedman’s test was used.Kruskal^Wallis
variance analysis was used for detecting the di¡erence of
dyspnoea scores between groups. For assesment of cor-
responding PEFR in di¡erent groups, univariate variance
analysis and Tukey’s post hoc comparison testwereused.
Fisher’s exact chi-square test was used for analysing the
di¡erence of adverse events and number of rescuemedi-
cations between groups.
RESULTS
Seventy patients were randomised and all the patients
completed the study.Table1lists baseline characteristics.
The baseline characteristics were similar in all groups.
The percentage change from baseline in PEFR over the
24h following treatment is shown in Fig.1.Those receiv-
ing steroid and steroidplusmontelukastgrouphad signif-
icantly better PEFR values than the placebo (Po0.05).
The increase in airway function was sustained over
the entire 24h period.The percentage change di¡erence
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FIG. 1. Percentage change frombaseline in PEFRover the 24 h following treatment.
EFFECTSOFORALMONTELUKAST 535between steroid plus montelukast and steroid favoured
the steroidplusmontelukast groupbutdidnotreach sta-
tistical signi¢cance. The mean maximum percentage in-
creases in PEFR frombaseline over the 24h period were
42, 39.9 and 10.3% for montelukast plus steroid, steroid
and placebo, respectively.
Borg dyspnoea score was signi¢cantly lower in the
treatment groups (1.870.9, 1.770.9) than in the placebo
(2.471.1, P=0.026).On the other hand, there was no dif-
ference between the treatment groups (P=0.34). The
steroid plus montelukast group required less inhaled
short-acting b agonist (0.871.1) than steroid group
(1.671.2) as a rescue medication. But the di¡erence be-
tween these two groups and placebo was not signi¢cant
(P=0.064).
There were no severe adverse experiences. The fre-
quency of adverse events was similar in the three treat-
mentgroups.Themost frequent adverse events included
malaise (8%) and headache (6%), which occurred in the
steroid addedmontelukast group.
DISCUSSION
This study shows adding oralmontelukast to intravenous
steroid causes some additive bene¢ts in pulmonary func-
tion in patients with acute asthma who have already re-
ceived ¢rst line treatment. Furthermore, the improved
air£ow persisted throughout the entire 24-h treatment
period with combined therapy.This clinical action might
be due to leukotriene receptor antagonists dual action
whichrelieves the e¡ects of an endogenous bronchocon-strictor and has an e¡ect on airway in£ammation (3).To
our knowledge, this study is the only direct comparison
of cysteinyl leukotriene receptor antagonist plus steroid
and steroid alone in acute asthma.
There is an unresolved debate about the use of sys-
temic corticosteroids in the early treatment of acute
asthma for emergency department patients (5). Corti-
costeroids require minimum of 6^12h to improve pul-
monary function in patients with acute asthma and they
only a¡ect certain in£ammatory mediators involved in
asthma (2). In a recentmeta analysis, Rodrigo and Rodri-
go found no evidence for either rapid (o6h) improve-
ment of pulmonary function or reduction in hospital
admission rates in patients with acute asthma (6). In an-
other study,Linetal. showedno earlybene¢tofparenteral
corticosteroids in adult asthmatic patients who present
with acute severe asthma (7). In addition, addingeither an-
ticholinergic agents (8,9) or methylxanthines (10,11) to b
agonists do not result in increased therapeutic e⁄cacy in
acute asthma.Taken together, these data suggest thatnew
agents that can enhance the bronchodilatory response in
acute asthma is needed and our study showed that leuko-
triene receptor antagonists might be a reasonable treat-
ment option in the setting of acute asthma.
In previous clinical studies, leukotriene receptor an-
tagonists have been shown to cause a rapid and clinically
signi¢cant bronchodilation after both oral and intrave-
nous administration in chronic asthma (4,12^15). In addi-
tion, they demonstrated a prompt improvement in lung
function with an additive e¡ect of inhaled b2 agonists
(4,13,15).Our present study adds to this spectrum of ac-
tivity by documenting additive bronchodilation following
536 RESPIRATORYMEDICINEoral administration of montelukast to patients with
acute asthmawho have received systemic corticosteroid
and inhaled b2 agonist.
Tmax of intravenousmontelukast is shorter than oral
montelukast (1h vs. 3 h) (16).Distribution ofmontelukast
to the lung cysteinyl leukotriene receptors would there-
fore be expected to bemore rapid with the intravenous
formulation, causing a greater increase in FEV1at the ear-
lier time points (17). This was well demonstrated in
Dockhorn et al.’s study (18). In that study, the onset of ac-
tion for intravenous montelukast was faster than oral
montelukast. It is therefore logical to consider intrave-
nous instead of oral formulation of montelukast in the
management of acute asthma.
Leukotriene receptor antagonistmightbemore e¡ec-
tive in acute severe asthma, since induced sputum cystei-
nyl leukotriene concentrations are signi¢cantly higher in
subjects with acute severe asthma than in patients with
milder asthma (19). Therefore, a study of montelukast in
acute severe asthma is warranted (20).The results of this
study will show whether leukotriene receptor antagonist
as second line treatmentwouldbebetter than aminophyl-
line or ipratropiumbromide in acute severe asthma.
Oral montelukast was found to be generally safe and
well toleratedin acute asthma.Adverse e¡ectswere few
and transient, with no apparent di¡erences between
treatments.Themost frequent adverse events werema-
laise and headache. No patient discontinued the study
because of an adverse experience.
In conclusion, this study demonstrated that the leuko-
triene receptor antagonist montelukast has the poten-
tial to provide additive clinical bene¢t in acute asthma
when administered concomitantly with corticosteroids.
However, a larger study with a greater power is neces-
sary to con¢rm these ¢ndings.
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